Fourth, upon treatment of tumor-bearing mice with VEGF-targeted compounds, tip and breach TECs were most sensitive, proliferating TECs were not more sensitive (likely indicating that other angiogenic signals were driving TEC proliferation), while venous TECs were less sensitive [6]. The gene discussed is VEGFA; the disease is neoplasm.